Health Care·Life Sciences Tools & Services·$7.8B
Bio-Rad Laboratories, Inc. (BIO) operates in the health care sector, specifically in life sciences tools and services....
EPS
Earnings per share is a key indicator of profitability and performance, which investors closely monitor.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
+20.84%
Avg Stock Reaction
-1.33%
In Q4-2025, Bio-Rad reported an EPS of $2.51, slightly missing the estimate of $2.57. The stock reacted negatively, declining by 0.43% the following day.
Management Promises & Guidance
Analysts expect Bio-Rad to report an EPS of $1.99 and revenue of $589 million for Q1-2026. The market is watching closely for any signs of growth or challenges in the life sciences sector.
Bull Case
If Bio-Rad exceeds EPS expectations, it could signal strong demand for its products and a positive outlook for the health care sector, potentially leading to a stock price increase.
Bear Case
Conversely, if the company misses its EPS target, it may indicate underlying issues in sales or market competition, leading to a negative reaction in the stock price.
EPS
$1.99Earnings per share is a key indicator of profitability and performance, which investors closely monitor.
Revenue
$589MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Bio-Rad's EPS exceed the consensus estimate of $1.99?
A beat on EPS could indicate stronger-than-expected demand and profitability, which would be a positive signal for investors.
Q2
What insights will management provide regarding revenue growth trends?
Understanding revenue growth will help assess the company's market position and future prospects, especially in a competitive landscape.
Why consensus could be wrong
The consensus may underestimate the potential for Bio-Rad to outperform due to its innovative product pipeline and strong customer relationships.
Supporting Evidence
Despite recent misses, Bio-Rad has a history of significant EPS surprises, indicating potential for strong performance.
The life sciences sector is experiencing increased demand, which may not be fully reflected in current estimates.
Key Risk
If Bio-Rad's revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a trend of mixed results, and investors are keen to see if the company can regain momentum.
Bull Confirmed If
An EPS of $2.10 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $1.86 would raise concerns about the company's growth trajectory and market challenges.
Implied Move
±N/A
There is no available options market data to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Bio-Rad beats expectations, history suggests the stock could see a modest increase, confirming a positive outlook for the company.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A miss on EPS could lead to a decline in stock price, with history indicating an average drop of around 1.89% following such outcomes.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026